FSC Wealth Advisors LLC Has $72,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

FSC Wealth Advisors LLC lessened its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 16.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 802 shares of the medical equipment provider’s stock after selling 160 shares during the quarter. FSC Wealth Advisors LLC’s holdings in Boston Scientific were worth $72,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC bought a new stake in shares of Boston Scientific during the second quarter worth $2,273,000. Kathmere Capital Management LLC acquired a new position in Boston Scientific in the 2nd quarter worth $201,000. Ascent Group LLC increased its holdings in Boston Scientific by 11.8% during the 2nd quarter. Ascent Group LLC now owns 7,480 shares of the medical equipment provider’s stock worth $576,000 after purchasing an additional 790 shares in the last quarter. Creative Planning raised its stake in shares of Boston Scientific by 13.7% in the 2nd quarter. Creative Planning now owns 189,545 shares of the medical equipment provider’s stock valued at $14,597,000 after purchasing an additional 22,901 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in shares of Boston Scientific by 34.0% in the second quarter. NewEdge Advisors LLC now owns 81,307 shares of the medical equipment provider’s stock valued at $6,261,000 after purchasing an additional 20,644 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares of the company’s stock, valued at $2,660,580.24. The trade was a 19.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,989 shares of company stock worth $2,702,261. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.3 %

Boston Scientific stock opened at $102.22 on Tuesday. The company’s 50-day moving average price is $92.26 and its two-hundred day moving average price is $85.45. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock has a market cap of $150.65 billion, a P/E ratio of 84.48, a P/E/G ratio of 2.63 and a beta of 0.80. Boston Scientific Co. has a twelve month low of $60.78 and a twelve month high of $102.32.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Friday, January 10th. Bank of America lifted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Finally, BTIG Research increased their price objective on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Three research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.